MND: Amarin corporation has publish results of a Phase III clinical trial of their AMR101 drug which is an ethyl icosapentate (ethyl-EPA).
- “..The MARINE study, investigating AMR101 as a treatment for very high triglycerides (≥500 mg/dL)”
- Reported results are significant ”….patient group treated with 4 grams of AMR101 showed a significant median TG decrease of 33 % (P < 0.0001) compared to placebo, and the patient group treated with 2 grams of AMR101 showed a significant median TG decrease of 20 % (P = 0.0051) compared to placebo…”
MND: so what is AMR101 and how does is differ from your over the counter fish oil supplement
Wiki’s page on Ethyl eicosapentaenoic acid defines it as : “….Ethyl eicosapentaenoic acid (E-EPA) is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA)…”
It is has possible application on:
MND: For background on Omega’s, we are going to link you to the Linus Pauling/U. of Oregon site. But what makes this synthetic so much more potent?
MND:Another aspect of this E-EPA potential is about Huntington’s Disease as discuused on the HDLighthouse site .
Still not clear what makes E-EPA proprietary and “pharmaceutical” , except perhaps the route of clinical trials?
We have left the “Nutrition” field….